[1]薛超 吴弘.脑利尿钠肽及N末端脑钠肽前体在心肾综合征患者中的应用进展[J].心血管病学进展,2023,(6):546.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.015]
　XUE Chao,WU Hong.Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Application in Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2023,(6):546.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.015]
点击复制

脑利尿钠肽及N末端脑钠肽前体在心肾综合征患者中的应用进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年6期
页码:
546
栏目:
综述
出版日期:
2023-06-25

文章信息/Info

Title:
Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Application in Cardiorenal Syndrome
作者:
薛超1; 2 吴弘 1
(1.海军军医大学附属长海医院心内科,上海,200433;2.海军军医大学海军特色医学中心心内科,上海,200052)
Author(s):
XUE Chao1; 2; WU Hong1
Department of Cardiology,Changhai Hospital,Naval Medical University,Shanghai 200433, China2.Department of Cardiology,Naval Special Medical Center,Naval Medical University,Shanghai 200052,China)
关键词:
脑利尿钠肽; N末端脑钠肽前体; 心肾综合征; 肾功能不全; 心力衰竭
Keywords:
Brain natriuretic peptide;  N-terminal pro-brain natriuretic peptide;  cardiorenal syndrome;  renal insufficiency;  heart failure
DOI:
10.16806/j.cnki.issn.1004-3934.2023.06.015
摘要:
心肾综合征(CRS)早期缺乏典型的症状和体征，诊断困难，预后较差，近年来其与脑利尿钠肽(BNP)和N末端脑钠肽前体(NT-proBNP)之间的关系受到广泛关注。BNP及NT-proBNP在心力衰竭诊断和评估中的价值已得到证实，肾功能不全也会引起二者增高，影响对心力衰竭严重程度的判断和评估，现综述BNP及NT-proBNP在CRS患者中的应用进展。
Abstract:
Cardiorenal syndrome(CRS) lacks typical symptoms and signs in the early stage,which is difficult to diagnose and has a poor prognosis. In recent years,it has been associated with BNP and NT-proBNP,which has attracted much attention. The value of BNP and NT-proBNP in the diagnosis and evaluation of heart failure has been confirmed. Renal insufficiency can also cause the increase of BNP and NT-proBNP,which affects the judgment and evaluation of the severity of heart failure. This article reviews the application progress of BNP and NT-proBNP in patients with cardiorenal syndrome

参考文献/References:

[1].Bongartz LG,Cramer MJ,Doevendans PA,et al. The severe cardiorenal syndrome:’guyton revisited’[J]. Eur Heart J,2005,26(1):11-17.
[2].Okamoto R,Ali Y,Hashizume R,et al. BNP as a major player in the heart-kidney connection[J].Int J Mol Sci,2019,20(14):3581.
[3].Nadar SK,Shaikh MM. Biomarkers in routine heart failure clinical care[J]. Card Fail Rev,2019,5(1):50-56.
[4].Schou M,Dalsgaard MK,Clemmesen O,et al. Kidneys extract BNP and NT-proBNP in healthy young men[J]. J Appl Physiol (1985),2005,99(5):1676-1680.
[5].McAlister FA,Ezekowitz J,Tonelli M,et al. Renal insufficiency and heart failure:prognostic and therapeutic implications from a prospective cohort study[J]. Circulation,2004,109(8):1004-1009.
[6].耿明霞,殷少华,马杰. BNP在诊断慢性心力衰竭患者早期肾功能变化中临床价值[J]. 国际检验医学杂志,2012,33(13):1652-1654.
[7].李岗峰,李刘文,刘璐. 慢性心力衰竭患者血清内源性Apela,NT-proBNP及Cys C水平与并发肾功能不全的相关性分析[J]. 现代检验医学杂志,2022,37(3):167-171.
[8].Dos Reis D,Fraticelli L,Bassand A,et al. Impact of renal dysfunction on the management and outcome of acute heart failure:results from the French prospective,multicentre,DeFSSICA survey[J]. BMJ Open,2019,9(1):e022776.
[9].Pfister R,Müller-Ehmsen J,Hagemeister J,et al. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure[J]. Intern Med J,2011,41(6):467-472.
[10].Takahama H,Nishikimi T,Takashio S,et al. Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure:A Novel Predictor Candidate for Cardiorenal Syndrome[J]. J Am Heart Assoc,2019,8(17):e011468.
[11].Ceyhun G, ?ztürk M, Kü?üksu Z, et al. B-type natriuretic peptide/ferritin ratio as a predictor of the risk of developing acute renal injury in acute decompensated heart failure[J]. Turk J Emerg Med,2021,21(3):98-103.
[12].Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT[J]. Eur Heart J,2004,25(4):292-299.
[13].Horii M,Matsumoto T,Uemura S,et al. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function[J]. J Cardiol,2013,61(6):410-416.
[14].van Kimmenade RR, Januzzi JL Jr, Baggish AL, et al. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure:redefining the cardiorenal interaction[J]. J Am Coll Cardiol,2006,48(8):1621-1627.
[15].deFilippi CR, Seliger SL, Maynard S,et al. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality[J]. Clin Chem,2007,53(8):1511-1519.
[16].Wettersten N,Horiuchi Y,van Veldhuisen DJ,et al. B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure[J]. Eur J Heart Fail,2019,21(12):1553-1560.
[17].Salah K,Kok WE,Eurlings LW,et al. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure[J]. JACC Heart Fail,2015,3(10):751-761.
[18].Stolfo D,Stenner E,Merlo M et al. Prognostic impact of BNP variations in patients admitted for acute decompensated heart failure with in-hospital worsening renal function[J]. Heart Lung Circ,2017,26(3):226-234.
[19].中国医师协会检验医师分会心血管专家委员会. B型利钠肽及N末端B型利钠肽前体实验室检测与临床应用中国专家共识[J]. 中华医学杂志,2022,102(35):2738-2754.
[20].Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure[J]. Eur J Heart Fail,2007,9(8):787-794.
[21].Jafri L,Kashif W,Tai J,et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide:selecting the optimal heart failure marker in patients with impaired kidney function[J]. BMC Nephrol,2013,14(undefined):117.
[22].Lamb EJ,Vickery S,Price CP. Amino-terminal pro-brain natriuretic peptide to diagnose congestive heart failure in patients with impaired kidney function[J]. J Am Coll Cardiol,2006,48(5):1060-1061.
[23].Yang JW, Kim MS, Kim JS, et al. Relationship between serum brain natriuretic peptide and heart function in patients with chronic kidney disease[J]. Korean J Intern Med,2008,23(4):191-200.
[24].Anwaruddin S,Lloyd-Jones DM,Baggish A,et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement:results from the proBNP investigation of dyspnea in the emergency department (PRIDE) study[J]. J Am Coll Cardiol,2006,47(1):91-97.
[25].McCullough PA,Duc P,Omland T,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure:an analysis from the breathing not properly multinational study[J]. Am J Kidney Dis,2003,41(3):571-579.
[26].Mueller C,McDonald K,de Boer RA,et al. Heart failure association of the european society of cardiology practical guidance on the use of natriuretic peptide concentrations[J]. Eur J Heart Fail,2019,21(6):715-731.
[27].Harrison TG,Shukalek CB,Hemmelgarn BR,et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD:a systematic review and meta-analysis[J]. Am J Kidney Dis,2020,76(2):233-247.
[28]. Khan SS,Ning H,Shah SJ, et al. 10-Year risk equations for incident heart?failure in the general population [J]. J Am Coll Cardiol,2019,73(19):2388-2397.
[29].Mehta R,Ning H,Bansal N,et al. Ten-year risk-prediction equations for incident heart failure hospitalizations in chronic kidney disease:findings from the chronic renal insufficiency cohort study and the multi-ethnic study of atherosclerosis[J]. J Card Fail,2022,28(4):540-550.
[30].Janus SE,Hajjari J,Chami T,et al. Multi-variable biomarker approach in identifying incident heart failure in chronic kidney disease:results from the chronic renal insufficiency cohort study[J]. Eur J Heart Fail,2022,24(6):988-995.
[31].Rangaswami J,Bhalla V,Blair JEA,et al. Cardiorenal syndrome:classification, pathophysiology, diagnosis, and treatment strategies:a scientific statement from the american heart association[J]. Circulation,2019,139(16):840-878.
[32].Plawecki M,Morena M,Kuster N,et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling:impact on risk prediction[J]. Mediators Inflamm,2018,2018(undefined):3952526.

相似文献/References:

[1]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]

更新日期/Last Update: 2023-07-21